I've been discussing this topic on Zulip with @The-King-of-Toasters (who's doing the actual work in #21440) over the past few weeks, but it's gotten to the point where some high-level decisions have ...

Sean is a JDM and off-road enthusiast of many years, and an automotive photographer. He holds a B.A. in Literature and Writing Studies, an A.A. in Communications, and an A.A. in English. He is ...

2025年10月29日，美国胸腺靶向药物研发商Zag Bio宣布完成A轮融资。本轮融资由AbbVie、Boxer Capital、JDRF T1D Fund、kdT Ventures、Lightspeed Ventures、Mission BioCapital、Pear Ventures、Polaris Partners、Regeneron Ventures和Sanofi ...

With a new approach to creating thymus-targeted medicines for autoimmune diseases, Zag Bio has emerged from stealth with the help of backing from pharma giants AbbVie, Regeneron and Sanofi. The trio ...

Discovery and development of the first systemic therapeutics to deliver self-antigens directly to the thymus to harness the body’s natural mechanism to induce central tolerance Lead program in Type 1 ...

John Kulman, then a senior research executive at CRISPR Therapeutics, was on vacation in Kennebunkport, Maine, three years ago when he snuck away to his laptop. The “vacation from his vacation,” he ...

CAMBRIDGE, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Zag Bio™, Inc., a biotechnology company pioneering thymus-targeted medicines, today announced the company’s launch with $80 million in financing, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A new Cambridge biotech company ...